Mentari Therapeutics merges with InMed Pharmaceuticals

Mentari Therapeutics is set to merge with InMed Pharmaceuticals in an all-stock transaction valued at $290 million, aimed at advancing the development of migraine prevention therapies. The merger will enable Mentari to operate under a new Nasdaq ticker symbol as it taps into InMed’s public market capabilities to potentially accelerate its therapeutic offerings.

The combined entity, to be known as Mentari Therapeutics, merges Mentari's migraine-focused drug development pipeline with InMed's public market infrastructure. The strategic move is designed to speed up the development of treatments for migraines, a condition affecting over a billion people globally. A key aspect of the merger includes a $290 million private placement led by Fairmount and backed by numerous investors such as Commodore Capital, Deep Track Capital, and Wellington Management. This financing aims to sustain operations through 2028.

Mentari's current lead programs, MT-001 and MT-002, target distinct migraine pathways and are positioned for regulatory filings by mid-2026 and early 2027, respectively. These programs aim to offer solutions to patients who have seen limited benefits from current anti-CGRP medications. Given that conventional migraine treatments do not achieve a 50% reduction in monthly migraine days for approximately 40% to 50% of patients, Mentari potentially addresses this gap with its innovative therapies.

The merger reflects a significant consolidation in the pharmaceutical sector, particularly within the realm of migraine treatment, which has seen heightened focus due to unmet medical needs. InMed shareholders will own about 1.51% of the combined company's pro forma equity, estimated at $421.4 million, inclusive of the merger financing. The new board will largely consist of Mentari's existing directors, chaired by Julie Bruno from Fairmount, with input from other notable names including Michelle Pernice from Fairmount and Laura Sandler of Oruka Therapeutics.

The boards of both companies have approved the merger, which is anticipated to close in the latter half of 2026, pending shareholder approvals, SEC green light, and other traditional closing conditions. Mentari's drug programs, rooted in discoveries by Paragon Therapeutics, show promising in vitro potency, underpinning optimistic market projections. As the combined company gears up to redefine the treatment landscape for migraines, it positions itself amidst competitive dynamics requiring innovative approaches and robust market strategies.